Ventricular tachycardia future or investigational therapies: Difference between revisions
Hudakarman (talk | contribs) |
Hudakarman (talk | contribs) |
||
| Line 4: | Line 4: | ||
== Overview == | == Overview == | ||
Pharmacologic therapy for preventing VAs has yielded disappointing results in recent years. Therapy has been limited because of variable efficacy, pro-arrhythmic effects, patient compliance, and adverse effects from long-term therapy. As adjuvant suppressive therapy in patients with ICDs, amiodarone and sotalol have been shown to reduce the rate of recurrent VT (71% and 15–44%, respectively) when compared with beta-blockers or placebo 40. Current guidelines recommend pharmacologic therapy (amiodarone or sotalol) with or without adjunctive catheter ablation to prevent VT/VF recurrence and reducing ICD shocks | Pharmacologic therapy for preventing VAs has yielded disappointing results in recent years. Therapy has been limited because of variable efficacy, pro-arrhythmic effects, patient compliance, and adverse effects from long-term therapy. As adjuvant suppressive therapy in patients with ICDs, amiodarone and sotalol have been shown to reduce the rate of recurrent VT (71% and 15–44%, respectively) when compared with beta-blockers or placebo 40. Current guidelines recommend pharmacologic therapy (amiodarone or sotalol) with or without adjunctive catheter ablation to prevent VT/VF recurrence and reducing ICD shocks <ref name="pmid28721212">{{cite journal| author=Batul SA, Olshansky B, Fisher JD, Gopinathannair R| title=Recent advances in the management of ventricular tachyarrhythmias. | journal=F1000Res | year= 2017 | volume= 6 | issue= | pages= 1027 | pmid=28721212 | doi=10.12688/f1000research.11202.1 | pmc=5497814 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28721212 }}</ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 22:25, 6 March 2020
|
Ventricular tachycardia Microchapters |
|
Differentiating Ventricular Tachycardia from other Disorders |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Ventricular tachycardia future or investigational therapies On the Web |
|
FDA on Ventricular tachycardia future or investigational therapies |
|
CDC onVentricular tachycardia future or investigational therapies |
|
Ventricular tachycardia future or investigational therapies in the news |
|
Blogs on Ventricular tachycardia future or investigational therapies |
|
to Hospitals Treating Ventricular tachycardia future or investigational therapies |
|
Risk calculators and risk factors for Ventricular tachycardia future or investigational therapies |
Overview
Pharmacologic therapy for preventing VAs has yielded disappointing results in recent years. Therapy has been limited because of variable efficacy, pro-arrhythmic effects, patient compliance, and adverse effects from long-term therapy. As adjuvant suppressive therapy in patients with ICDs, amiodarone and sotalol have been shown to reduce the rate of recurrent VT (71% and 15–44%, respectively) when compared with beta-blockers or placebo 40. Current guidelines recommend pharmacologic therapy (amiodarone or sotalol) with or without adjunctive catheter ablation to prevent VT/VF recurrence and reducing ICD shocks [1]
References
- ↑ Batul SA, Olshansky B, Fisher JD, Gopinathannair R (2017). "Recent advances in the management of ventricular tachyarrhythmias". F1000Res. 6: 1027. doi:10.12688/f1000research.11202.1. PMC 5497814. PMID 28721212.